Blood management - Issues: The panic of coagulopathic bleeding - Is there a rational approach?

Journal of Extra-Corporeal Technology

Volumn 43, Issue 1, 2011, Pages

  Spiess, Bruce D ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bleeding; Coagulation; Coagulopathy; Fresh frozen plasma; Heparin; Monitoring; Platelets; Thromboelastography

Indexed keywords

PROCOAGULANT;

ADVERSE OUTCOME; ALGORITHM; BLOOD; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; FEAR; HEART SURGERY; HEMATOCRIT; HEREDITY; HUMAN; LABORATORY; PANIC; PHYSICIAN; WASTE;

EID: 79952923478     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Spiess BD, Harrow J, Kaplan JA. Transfusion medicine and coagulation disorders. In: Kaplan JA, Reich DL, Lake CL, Konstadt SN, eds. Kaplan's Cardiac Anesthesia, 5th Ed. Philadelphia, PA: Saunders Elsvevier; 2006:937-84.
2. Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery. The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(Suppl):S27-86. Review.
3. Duggan E, O'Dwyer MJ, Caraher E, et al. Coagulopathy after cardiac surgery may be influenced by a functional plasminogen activator inhibitor polymorphism. Anesth Analg. 2007;104:1343-7. (Pubitemid 46791264)
4. Welsby IJ, Padgoreanu MV, Phillips-Bute B, et al. Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost. 2005;3:1206-12. (Pubitemid 41725243)
5. Tantry US, Bliden KP, Suarez TA, Kreutz RP, Kichiara J, Gurbel PA. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: Results of the Thrombotic Risk Progression (TRIP) study. Platelets. 2010;21:360-7.
6. Pineda J, Marin F, Marco P, et al. Premature coronary artery disease in young age (<45) subjects: Interactions of lipid profile, thrombophillic and hemostatic markers. Int J Cardiol. 2009;136:222-5.
7. Zorio E, Gilabert-Estelles J, Espana F, Ramon LA, Cosin R, Estelles A. Fibrinolysis: The key to new pathogentic mechanisms. Curr Med Chem. 2008;15:923-9. (Pubitemid 351736413)
8. Benza RL, Grennett HE, Bouge RC, et al. Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. Circulation. 1998;98:2248-54. (Pubitemid 28533842)
9. Boekholdt SM, Peters RJ, de Maat MP, et al. Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events. Am Heart J. 2004;14:181-6. (Pubitemid 38037416)
10. Zotz RB, Winkelmann BR, Muller C, Boehm BO, Marz W, Scharf RE. Association of polymorphisms of platelet membrane integrins alpha IIb(beta)3 (HPA-1bPI) and alpha 2 (beta)1(alpha8077TT) with premature myocardial infarction. J Thromb Haemost. 2005;3:1522-9.
11. Pivalizza EG. TEG and perioperative hypercoagulability. Anesth Analg. 2006;102:334-5.
12. Akay OM, Ustumer Z, Canturk Z, Mutlu FS, Gulbas Z. Laboratory investigation of hypercoagulability in cancer patients rotation thromboelastography. Med Oncol. 2009;26:358-64.
13. Kashuk JL, Moore EE, Sable A, et al. Rapid thromboelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery. 2009;146:764-72.
14. Ascione R, Ghosh A, Rogers CA, Cohen A, Monk C, Angelini GD. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: A word of caution. Ann Thorac Surg. 2005;79:1210-6.
15. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2004;128:425-31. (Pubitemid 39194700)
16. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg. 2004;78:1536-41.
17. Kapetanakis EI, Medlam DA, Boyce SW, et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: The cardiologist's panacea or the surgeon's headache? Eur Heart J. 2005;26:576-83.
18. Ray JG, Deniz S, Olivieri A, et al. Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel. BMC Cardiovasc Disord. 2003;3:3.
19. Godino C, Mednolicchio L, Figini F, et al. Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel? Thromb J 2009;7:4.
20. Dyszkiewicz-Korpanty AM, Kim A, Burner JD, Frenkel EP, Sarode R. Comparison of a rapid platelet function assay-Verfiy Now Aspirin-with whole blood impedance aggregometry for the detection of aspirin resistance. Thromb Res. 2007;120:485-8. (Pubitemid 47094907)
21. Spiess BD. Con: Continuation of aspirin/clopidogrel for cardiac surgery. J Cardiothorac Anesth. 2007;21:606-9. (Pubitemid 47126919)
22. Gravlee GP, Arora S, Lavender SW, et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg. 1994;58:216-21. (Pubitemid 24243933)
23. Spiess BD. A little coagulation knowledge can be dangerous. Can J Anaesth. 2009;56:478-82.
24. Borsig L. Antimetastatic activities of heparin and modified heparins. Experimental evidence. Thromb Res. 2010;125:S66-71.
25. Casu B, Naggi A, Torri G. Heparin-derived heparan sulfate mimics to modulate heparin sulfate-protein interactions in inflammation and cancer. Matrix Biol. 2010;29:442-52.
26. Lever R, Smailbegovic R, Page CP. Locally available heparin modulates inflammatory-cell recruitment in a manner independent of anticoagulant activity. Eur J Pharmacol. 2010;630:137-44.
27. Li JP, Vlodavsky I. Heparin, heparin sulfate and heparanase in inflammatory reactions. Thromb Haemost. 2009;102:823-8.
28. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: Host associated molecular patterns for initiation and modulation of inflammation. FASEB. 2006;20:9-22. (Pubitemid 43100470)
29. Vlodovsky I, Ilan N, Naggi A, Casu B. Heparanase: Structure, biological functions and inhibition by heparin-derived mimetics of heparin sulfate. Curr Pharm Des. 2007;13:2057-73. (Pubitemid 47044735)
30. Borawski J, Gozdzikiewiz J, Dubowski M, Pawalak K, Mysliwiec M. Tissue factor pathway inhibitor release and depletion of sulodexide in humans. Adv Med Sci. 2009;54:32-6.
31. Ilhrcke NS, Platt JL. Shedding of heparin sulfate proteoglycan by stimulated endothelial cells: Evidence for proteolysis of cell-surface molecules. J Cell Physiol. 1996;168:625-37. (Pubitemid 26302869)
32. Eisses MJ, Velan T, Aldea GS, Chandler WL. Strategies to reduce hemostatic activation during cardiopulmonary bypass. Thromb Res. 2006;117:689-703.
33. O'Gara PJ, Aldea GS, Shemin RJ, Shapira OM. Heparin-bonded circuit with low systemic anticoagulation in a patient with heparin-induced thrombocytopenia: A case report. J Extra Corpor Technol. 1999;31:142-4. (Pubitemid 30054126)
34. Paparella D, Al Radi OO, Meng QH, Venner T, Teoh K, Young E. The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2005;16:323-8. (Pubitemid 41008738)
35. Warkentin TE, Crowthen MA. Reversing anticoagulants both old and new. Can J Anaesth. 2002;49:811-25.
36. Bruins P, te Velthuis H, Eerenberg-Belmer AJ, et al. Heparinprotamine complexes and C-reactive protein induced activation of the classical complement pathway: Studies in patients undergoing cardiac surgery and in vitro. Thromb Haemost. 2000;84:237-43.
37. Shibamiya A, Tabuchi N, Chung J, Suanori M, Koyama T. Formation of tissue factor-bearing leukocytes during and after cardiopulmonary bypass. Thromb Haemost. 2004;92:124-31. (Pubitemid 39010875)
38. Chandler WL, Velan T. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass. Thromb Res. 2003;112:185-92.
39. Yavari M, Becker RC. Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. J Thromb Thrombolysis. 2009;27:95-104.
40. Chandler WL, Velan T. Plasmin generation and D-dimer formation during cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2004;15:583-91.
41. Chandler WL, Fitch JCK, Wall MH, et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost. 1995;74:1293-7.
42. Despotis GJ, Avidan MS, Hogue CW. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg. 2001;72:S1821-31.
43. Karkouti K, McClusky S, Syed S, Pazaratz C, Poonawala H, Crowther M. The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: A prospective observational study. Anesth Analg. 2010;110:1533-40.
44. Beckman SR, Carlile D, Bissinger RC, Burrell M, Winkler T, Shely WW. Improved coagulation and blood conservation in the golden hours after cardiopulmonary bypass. J Extra Corpor Technol. 2007;39:103-8. (Pubitemid 351506726)
45. Diamanti M, Tushuizen ME, Sturk A, Niwland R. Cellular microparticles: New players in the field of vascular disease? Eur J Clin Invest. 2004;34:392-401.
46. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40 and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108:2455-62. (Pubitemid 44497533)
47. Moganansundram S, Hunt BJ, Sykes K, et al. The relationship among thromboelastography, hemostatic variables, and bleeding after cardiopulmonary bypass surgery in children. Anesth Analg. 2010;110: 995-1002.
48. Hertfelden HJ, Bos M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost. 2005;31:426-40. (Pubitemid 41362349)
49. Cherng YG, Chao A, Shih RL, et al. Preoperative evaluation and postoperative prediction of hemostatic function with thromboelastography in patients undergoing redo cardiac surgery. Acta Anaesthesiol Sin. 1998;36:179-89.
50. Kettner SC, Kozck SA, Groetzner JP, et al. Effects of hypothermia on thromboelastography in patients undergoing cardiopulmonary bypass. Br J Anaesth. 1998;80:313-7. (Pubitemid 28105464)
51. Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg. 2003;96:51-7. (Pubitemid 36042031)
52. Preisman S, Kogan A, Itzkovsky K, Leikin G, Raanani E. Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. Eur J Cardiothorac Surg. 2010;37:1367-74.
53. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999;88:312-9. (Pubitemid 29070189)
54. Enriquez LJ, Shore-Lesserson L. Point-of-care coagulation testing and transfusion algorithms. Br J Anaesth. 2009;103:114-22.
55. Despotis GJ, Skubas NJ, Goodnough LT. Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Semin Thorac Cardiovasc Surg. 1999;11:84-104.
56. Cattaneo M. The use of desmopressin in open heart surgery. Haemophilia. 2008;14:S40-7.
57. Weber CF, Dietrich W, Spannagl M, Hofstetter C, Jambor C. A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole blood aggregometry in patients after cardiac surgery. Anesth Analg. 2010;110:702-7.
58. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology. 1992;77:38-46.
59. Wang X, Zheng Z, Ao H, et al. A comparison before and after aprotinin was suspended in cardiac surgery: Different results in the real world from a single cardiac center in China. J Thorac Cardiovasc Surg. 2009;138:897-903.
60. Willis CD, Cameron PA, Phillips LE. Clinical guidelines and off-license recombinant activated factor VII: Content, use and association with patient outcomes. J Thromb Haemost. 2009;7:2016-22.